Developments in the treatment of visceral leishmaniasis

Hdl Handle:
http://hdl.handle.net/10144/127729
Title:
Developments in the treatment of visceral leishmaniasis
Authors:
den Boer, Margriet Leontine; Alvar, Jorge; Davidson, Robert N; Ritmeijer, Koert; Balasegaram, Manica
Journal:
Expert Opinion on Emerging Drugs
Abstract:
BACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontinent and Africa. OBJECTIVE: This review aims to describe the potential and the (lack of) current impact of newly developed treatments on the control of VL. It describes how the problem of an empty research pipeline is addressed, and discusses the emerging threat of incurable HIV/VL coinfection. METHODS: The literature was searched for drugs used in VL. CONCLUSION: Research and development of VL drugs has received a financial boost but no new drugs are expected in the next 5 years. Only three new and highly effective treatments have been licensed in the past 10 years. These remain, however, largely inaccessible as VL control programs in the developing world are lacking. This is deserving of immediate and urgent attention, especially in the context of the rapidly expanding HIV/VL coinfection.
Affiliation:
Medecins Sans Frontieres, Amsterdam, The Netherlands
Issue Date:
1-Sep-2009
URI:
http://hdl.handle.net/10144/127729
DOI:
10.1517/14728210903153862
PubMed ID:
19708817
Additional Links:
http://informahealthcare.com/doi/abs/10.1517/14728210903153862
Submitted date:
2010-10-15
Type:
Article
Language:
en
ISSN:
1744-7623
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorden Boer, Margriet Leontineen
dc.contributor.authorAlvar, Jorgeen
dc.contributor.authorDavidson, Robert Nen
dc.contributor.authorRitmeijer, Koerten
dc.contributor.authorBalasegaram, Manicaen
dc.date.accessioned2011-04-07T16:07:15Z-
dc.date.available2011-04-07T16:07:15Z-
dc.date.issued2009-09-01-
dc.date.submitted2010-10-15-
dc.identifier.citationExpert Opin Emerg Drugs2009;14 (3):395-410en
dc.identifier.issn1744-7623-
dc.identifier.pmid19708817-
dc.identifier.doi10.1517/14728210903153862-
dc.identifier.urihttp://hdl.handle.net/10144/127729-
dc.description.abstractBACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontinent and Africa. OBJECTIVE: This review aims to describe the potential and the (lack of) current impact of newly developed treatments on the control of VL. It describes how the problem of an empty research pipeline is addressed, and discusses the emerging threat of incurable HIV/VL coinfection. METHODS: The literature was searched for drugs used in VL. CONCLUSION: Research and development of VL drugs has received a financial boost but no new drugs are expected in the next 5 years. Only three new and highly effective treatments have been licensed in the past 10 years. These remain, however, largely inaccessible as VL control programs in the developing world are lacking. This is deserving of immediate and urgent attention, especially in the context of the rapidly expanding HIV/VL coinfection.en
dc.language.isoenen
dc.relation.urlhttp://informahealthcare.com/doi/abs/10.1517/14728210903153862en
dc.rightsArchived with thanks to Expert Opinion on Emerging Drugsen
dc.subject.meshAfricaen
dc.subject.meshAnimalsen
dc.subject.meshAntiprotozoal Agentsen
dc.subject.meshDeveloping Countriesen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshHumansen
dc.subject.meshLeishmaniaen
dc.subject.meshLeishmaniasis, Visceralen
dc.titleDevelopments in the treatment of visceral leishmaniasisen
dc.typeArticleen
dc.contributor.departmentMedecins Sans Frontieres, Amsterdam, The Netherlandsen
dc.identifier.journalExpert Opinion on Emerging Drugsen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.